SEQUANA MEDICAL NV
Company profile
Sequana Medical is a commercial stage company specialized in the development of medical devices for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders. In particular, the group offers the alfapump®, a fully implantable, programmable system with CE mark for the management of refractory ascites (chronic accumulation of fluid in the abdomen) due to cirrhosis of the liver, and malignant ascites (with a life expectancy of six months or less).
Sequana Medical is also developing alfapump® DSR, a novel and proprietary approach to the treatment of volume overload in heart failure.
Source: Cofisem - Last Update: 06 Dec 2019
Key Executives
| Chief Executive Officer | Ian Crosbie | ||||
| Chief Financial Officer | Kirsten Van Bockstaele | ||||
| VP, Investor Relations | Lies Vanneste | ||||
| Source: Cofisem - Last Update: 07 May 2019 | |||||
Key figures
| Millenium | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|
| Net sales | 1,029 | 1,304 | 1,489 | 1,685 | |
| Income from ordinary activities | 1,029 | 1,304 | 1,489 | 1,685 | |
| Operating income | -13,077 | -7,418 | -13,945 | -11,356 | |
| Cost (net) of financial indebtedness | -922 | -635 | -187 | -84 | |
| Equity-accounted companies' contribution to results | |||||
| Net profit from discontinued activities | |||||
| Net income | -13,983 | -8,225 | -13,975 | -11,557 | |
| Net income (Group share) | -13,983 | -8,225 | -13,975 | -11,557 | |
| Fiscal year end | 12.18 | 12.17 | 12.16 | 12.15 | |
| Length of fiscal year (month) | 12 | 12 | 12 | 12 | |
| Currency & Unit | EUR - thousands | EUR - thousands | EUR - thousands | EUR - thousands | |
| Account Standards | |||||
| Source: Cofisem - Last Update: 06 Dec 2019 | |||||